Surrozen, Inc. SRZN

SRZN Company Overview

Surrozen, Inc. is a clinical-stage biotechnology company focused on developing therapeutics that modulate the Wnt signaling pathway for tissue repair and regeneration. The company operates within the biotechnology and biopharmaceutical industries, with a primary emphasis on regenerative medicine, liver disease, gastrointestinal disorders, ophthalmology, and other conditions involving damaged or diseased tissue. Surrozen’s core scientific platform is designed to selectively activate Wnt signaling in targeted tissues through engineered antibody-based therapeutics and fusion proteins.

The company’s primary value drivers have historically centered on its proprietary Wnt biology platform, preclinical research capabilities, and advancement of clinical-stage candidates. Surrozen was founded based on research originating from Stanford University and has evolved from an early-stage platform company into a publicly traded biotechnology firm focused on translational and clinical development. Its strategic positioning is tied to specialized expertise in Wnt pathway modulation, an area historically considered difficult to target safely due to the pathway’s broad biological role.